1 Citation, commencement and interpretation

(1)    This Order may be cited as the Medicines for Human Use (Prohibition) (Senecio and Miscellaneous Amendments) Order 2008 and shall come into force on 1st April 2008.

(2)    In article 3—

“the Act” means the Medicines Act 1968;

“external use” means application to the skin, hair, teeth, mucosa of the mouth, throat, nose, ear, eye, vagina or anal canal when a local action only is intended and extensive systemic absorption is unlikely to occur;

“free circulation in member States” has the same meaning as in Article 23.2, as read with Article 24, of the Treaty establishing the European Community;

“third country” means any country other than an EEA State.

NOTES
Initial Commencement
Specified date

Specified date: 1 April 2008: see para (1) above.

2 Prohibition of sale, supply and importation of any medicinal product consisting of or containing Senecio

2Prohibition of sale, supply and importation of any medicinal product consisting of or containingSenecio

Except as provided for in article 3, the sale, supply or importation of any medicinal product consisting of or containing—

(a)    a plant belonging to the species Senecio; or

(b)    an extract from such a plant,

is prohibited.

NOTES
Initial Commencement
Specified date

Specified date: 1 April 2008: see art 1(1).

Pharmacy, Drugs & Medicinal Products91 Health Law91

3 Exceptions to the prohibition imposed by article 2

3Exceptions to the prohibition imposed by article 2

The prohibition imposed by article 2 shall not apply where the medicinal product is—

(a)    

(i)    for external use only; and

(ii)    not a teething preparation, throat spray, throat pastille, throat lozenge, throat tablet, nasal spray or nasal inhalation or nasal drops;

(b)    sold or supplied to, or imported by or on behalf of, any of the following persons—

(i)    an authorised officer within the meaning of section 5(6) of the Food Safety Act 1990 or Article 2(2) of the Food Safety (Northern Ireland) Order 1991,

(ii)    a food analyst or food examiner within the meaning of section 30 of the Food Safety Act 1990 or Article 30 or 31 of the Food Safety (Northern Ireland) Order 1991,

(iii)    a person duly authorised by an enforcement authority under sections 111 and 112 of the Act, or

(iv)    a sampling officer within the meaning of paragraph 1(1) of Schedule 3 to the Act;

(c)    imported from an EEA State, if the product—

(i)    originates in an EEA State, or

(ii)    originates outside the European Economic Area, but is in free circulation in member States,

and is being, or is to be, exported to a third country or an EEA State other than the United Kingdom; or

(d)    the subject of—

(i)    a product licence,

(ii)    a marketing authorization within the meaning given in regulation 1(4)(a) of the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994,

(iii)    a certificate of registration within the meaning of regulation 2(2) of the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994, or

(iv)    a traditional herbal registration within the meaning given in regulation 2(1) of the Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005.

NOTES
Initial Commencement
Specified date

Specified date: 1 April 2008: see art 1(1).

Pharmacy, Drugs & Medicinal Products90 Food & Drugs95 Consumer Law95 Health Law90

4 Amendment of the Medicines (Bal Jivan Chamcho Prohibition) (No 2) Order 1977

4Amendment of the Medicines (Bal Jivan Chamcho Prohibition) (No 2) Order 1977

(1)    The Medicines (Bal Jivan Chamcho Prohibition) (No 2) Order 1977 is amended as follows.

(2)    In article 2—

(a)    for paragraph (4) substitute—

“(4)    The prohibition imposed by paragraph (1) above shall not apply where the medicinal product is imported from an EEA State, if the product—

(a)    originates in an EEA State, or

(b)    originates outside the European Economic Area, but is in free circulation in member States,

and is being, or is to be, exported to a third country or an EEA State other than the United Kingdom.”; and

(b)    after paragraph (4), insert—

“(5)    For the purposes of paragraph (4)—

“free circulation in member States” has the same meaning as in Article 23.2, as read with Article 24, of the Treaty establishing the European Community;

“third country” means any country other than an EEA State.”.

NOTES
Initial Commencement
Specified date

Specified date: 1 April 2008: see art 1(1).

Pharmacy, Drugs & Medicinal Products91 Health Law91

5 Amendment of the Medicines (Aristolochia and Mu Tong etc) (Prohibition) Order 2001

5Amendment of the Medicines (Aristolochia and Mu Tong etc) (Prohibition) Order 2001

(1)    The Medicines (Aristolochia and Mu Tong etc) (Prohibition) Order 2001 is amended as follows.

(2)    In article 1 (citation, commencement and interpretation), in paragraph (2)—

(a)    after the definition of “the Act”, insert—

““free circulation in member States” has the same meaning as in Article 23.2, as read with Article 24, of the Treaty establishing the European Community;”;

(b)    omit the definitions of “EEA Agreement” and “EEA State”;

(c)    after the definition of “medicinal product”, insert—

“third country” means any country other than an EEA State.”.

(3)    In article 4, for paragraph (3), substitute—

“(3)    The prohibition imposed by articles 2 and 3 above shall not apply where the medicinal product is imported from an EEA State, if the product—

(a)    originates in an EEA State, or

(b)    originates outside the European Economic Area, but is in free circulation in member States,

and is being, or is to be, exported to a third country or an EEA State other than the United Kingdom.”.

NOTES
Initial Commencement
Specified date

Specified date: 1 April 2008: see art 1(1).

Pharmacy, Drugs & Medicinal Products91 Health Law91

6 Amendment of the Medicines for Human Use (Kava-kava) (Prohibition) Order 2002

6Amendment of the Medicines for Human Use (Kava-kava) (Prohibition) Order 2002

(1)    The Medicines for Human Use (Kava-kava) (Prohibition) Order 2002 is amended as follows.

(2)    In article 1(2)—

(a)    omit the definitions of “EEA Agreement” and “EEA State”;

(b)    after the definition of “medicinal product”, insert—

“third country” means any country other than an EEA State.”.

(3)    In article 3, for paragraph (c), substitute the following—

“(c)    imported from an EEA State, if the product—

(i)    originates in an EEA State, or

(ii)    originates outside the European Economic Area, but is in free circulation in member States,

and is being, or is to be, exported to a third country or an EEA State other than the United Kingdom.”.

NOTES
Initial Commencement
Specified date

Specified date: 1 April 2008: see art 1(1).

Pharmacy, Drugs & Medicinal Products91 Health Law91

Signature

Signed by authority of the Secretary of State for Health.

Dawn Primarolo

Minister of State,

Department of Health

28th February 2008

Michael McGimpsey

Minister for Health,

Social Services and Public Safety

27th February 2008

EXPLANATORY NOTE

EXPLANATORY NOTE (This note is not part of the Order)

This Order prohibits the sale, supply or importation of any medicinal product for human use which consists of or contains a plant, or part of a plant, belonging to the species Senecio or an extract from such a plant.

This prohibition is subject to exceptions.

This Order also makes minor amendments to three existing Orders made under section 62 of the Medicines Act 1968: the Medicines (Bal Jivan Chamcho Prohibition) (No 2) Order 1997 (SI 1977/670); the Medicines (Aristolochia and Mu Tong etc) (Prohibition) Order 2001 (SI 2001/1841); and the Medicines for Human Use (Kava-kava) (Prohibition) Order 2002 (SI 2002/3170). The amendments ensure that the exception for goods in transit in the three Orders applies to goods imported from an EEA State which are to be exported to a third country or an EEA State other than the United Kingdom.

This Order was notified to the European Commission in accordance with Article 8 of the European Parliament and Council Directive 98/34/EC (OJ No L204, 21.7.1998, p 37), as amended by Article 1(4) of the European Parliament and Council Directive 98/48/EC (OJ No L217, 5.8.1998, p 18).

A full regulatory impact assessment of the effect that this instrument will have on the costs of business is available from the Medicines and Healthcare products Regulatory Agency, Information Centre, Room 10–202, Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Copies have been placed in the libraries of both Houses of Parliament.